ReviewCancers2022
Early Palliative Care in Acute Myeloid Leukemia.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- Understanding the evolving role of early palliative care in myelodysplastic syndromes: a 2026 narrative review.Annals of hematology · 2026Review
- Quality of life and symptoms in acute myeloid leukaemia with early palliative care: real-world observational study.BMJ supportive & palliative care · 2026Observational
- Trends in incidence and mortality of acute and chronic leukaemias in Brazil: challenges and advances over three decades.Ecancermedicalscience · 2026Article
- How to Read a Next-Generation Sequencing Report for AML and MDS? What Hematologists Need to Know.Journal of clinical medicine · 2025Review
- Understanding challenges and barriers to quality end-of-life care for patients with hematologic malignancies: a GIMEMA survey.Annals of hematology · 2025Article
- Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.Blood advances · 2025Review
- Menin Inhibitors: New Targeted Therapies for Specific Genetic Subtypes of Difficult-to-Treat Acute Leukemias.Cancers · 2025Review
- Quality of end-of-life care in patients with hematological malignancies: potential role of palliative care.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Observational
- Identifying research priorities and essential elements of palliative care services for people facing malignant brain tumors: A participatory co-design approach.Neuro-oncology practice · 2024Article
- Top Ten Tips Palliative Care Clinicians Should Know About Acute Myeloid Leukemia.Journal of palliative medicine · 2024Article
- "A strong reason why I enjoy coming to work": Clinician acceptability of a palliative and supportive care intervention (PACT) for older adults with acute myeloid leukemia and their care partners.Journal of geriatric oncology · 2024Article
- Article
- Positive Psychological Well-Being in Early Palliative Care: A Narrative Review of the Roles of Hope, Gratitude, and Death Acceptance.Current oncology (Toronto, Ont.) · 2024Review
- Article
- Pharmacists are initiators in palliative care for patients with rare diseases.Orphanet journal of rare diseases · 2023Article
- Advancing Palliative Care Integration in Hematology: Building Upon Existing Evidence.Current treatment options in oncology · 2023Review
- Caregiver's quality of life in advanced cancer: validation of the construct in a real-life setting of early palliative care.Frontiers in oncology · 2023Article
- Chimeric Antigen Receptor T-cell Therapy in Hematologic Malignancies and Patient-reported Outcomes: A Scoping Review.HemaSphere · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeveral novel targeted therapies seem to improve the outcome of acute myeloid leukemia (AML) patients. Nonetheless, the 5-year survival rate remains below 40%, and the trajectory of the disease remains physically and emotionally challenging, with little time to make relevant decisions. For patients with advanced solid tumors, the integration of early palliative care (EPC) with standard oncologic care a few weeks after diagnosis has demonstrated several benefits. However, this model is underutilized in patients with hematologic malignancies.
methodsIn this article, we analyze the palliative care (PC) needs of AML patients, examine the operational aspects of an integrated model, and review the evidence in favor of EPC integration in the AML course.
resultsAML patients have a high burden of physical and psychological symptoms and high use of avoidant coping strategies. Emerging studies, including a phase III randomized controlled trial, have reported that EPC is feasible for inpatients and outpatients, improves quality of life (QoL), promotes adaptive coping, reduces psychological symptoms, and enhances the quality of end-of-life care.
conclusionsEPC should become the new standard of care for AML patients. However, this raises issues about the urgent development of adequate programs of education to increase timely access to PC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.